Hospital.Help

London – A blood test from the Californian manufacturer Grail, which aims to detect up to 50 types of cancer at an early stage using the methylation patterns of cell-free DNA, has come under criticism even before the first results of the approval studies have been published. According to a report in the British medical journal (BMJ 2024; DOI: 10.1136/bmj.q1706), employees of the National Health Service (NHS) doubt the usefulness of the test. The “Galleri” test is part of a…